Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.45 |
| ▸ | PPARA | Q07869 | 14/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367031 | 0.87 | PPARG (0.39) | PPARGPPARAFFAR1CYP3A4 | |
| SCHEMBL131888 | 0.83 | PPARG (0.55) | PPARGPPARAFFAR1CYP3A4 | |
| SCHEMBL6052101 | 0.83 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL8030739 | 0.83 | PPARG (0.59) | PPARGPPARAFFAR1CYP3A4CYP2C9 | |
| SCHEMBL10682736 | 0.81 | PPARG (0.45) | PPARGPPARAFFAR1CYP3A4CYP2C9 | |
| SCHEMBL20755515 | 0.80 | PPARG (0.44) | PPARGPPARAFFAR1CYP3A4CYP2C9 | |
| SCHEMBL10366694 | 0.79 | MAOB (0.47) | PPARGPPARAFFAR1CYP3A4CYP2C9 | |
| SCHEMBL10852714 | 0.79 | PPARG (0.40) | PPARGPPARAFFAR1CYP3A4 | |
| SCHEMBL8458685 | 0.78 | PPARG (0.43) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL10365639 | 0.78 | PPARG (0.43) | PPARGPPARAFFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1522310-B1 | Therapeutic uses of Dunaliella powder | NIKKEN SOHONSHA CORP (JP) | 2012-03-07 | — | — | EP | claimed |
| EP-2269620-A1 | Therapeutic uses of dunaliella powder | Nikken Sohonsha Corporation (JP) | 2011-01-05 | — | — | EP | claimed |
| EP-0893995-B1 | ANTICACHECTIC COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-12-10 | — | — | EP | claimed |
| EP-0177353-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-04-11 | — | — | EP | claimed |
| US-4725610-A | TREATMENT OF HYPERLIPEMIA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | claimed |
| EP-0177353-A2 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-04-09 | — | — | EP | claimed |
| EP-1522310-B1 | Therapeutic uses of Dunaliella powder | NIKKEN SOHONSHA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-1047423-B1 | NOVEL APOPTOSIS INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | EP | disclosed |
| WO-2004045611-A1 | USE OF A THIAZOLIDINEDIONE FOR THE REDUCTION OF SIDE EFFECTS OF CHEMOTHERAPY | N-GENE RESEARCH LABORATORIES INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-0893995-B1 | ANTICACHECTIC COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-20020086883-A1 | Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-07-04 | — | — | US | disclosed |
| US-6399639-B1 | ADMINISTERING A 2,4-THIADIAZOLIDINEDIONE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| US-6365607-B1 | Anticachectic composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-02 | — | — | US | disclosed |
| US-6110948-A | Anticachectic composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| US-6087384-A | TREATING PROPHYLAXIS AND TREATMENT OF A DISEASE ASSOCIATE WITH DEATH OF CELLS CAUSED BY VIRAL DISEASES, MYELODYSPLASIS, NEURODEGENERATIVE, ISCHEMIC AND HEPATIC DISEASES WITH A COMPOUND HAVING AN INSULIN SENSITIVITY ENHANCING ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-1001768-A1 | METHODS OF INCREASING SENSITIVITY OF AN INDIVIDUAL TO OB PROTEIN BY UPREGULATING OB PROTEIN RECEPTOR | AMGEN INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999025346-A1 | NOVEL APOPTOSIS INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-27 | — | — | WO | disclosed |
| EP-0893995-A1 | ANTICACHECTIC COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998008512-A1 | METHODS OF INCREASING SENSITIVITY OF AN INDIVIDUAL TO OB PROTEIN BY UPREGULATING OB PROTEIN RECEPTOR | AMGEN INC. (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1997037656-A1 | ANTICACHECTIC COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086883-A1 | Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease | IRS1, IAPP, AIFM1 | PPARG 51/4885PPARA 24/4885FFAR1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.